Information Provided By:
Fly News Breaks for January 23, 2017
IRWD, SGYP
Jan 23, 2017 | 08:34 EDT
Roth Capital analyst Michael Higgins raised his price target for Synergy Pharmaceuticals (SGYP) to $10.50 from $6.50 after the FDA approved Trulance for the treatment of adults with chronic idiopathic constipation, and due to Synergy Pharmaceuticals lowered risk profile and to better align with the valuation of its peer Ironwood Pharmaceuticals (IRWD). He reiterates a Buy rating on Synergy Pharmaceuticals' shares.
News For SGYP;IRWD From the Last 2 Days
There are no results for your query SGYP;IRWD